A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Purpose

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

Condition

  • Non-small Cell Lung Cancer

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

for Neoadjuvant Therapy: - Pathologically documented NSCLC: - Newly diagnosed early-stage NSCLC stages IB, IIA, IIB, IIIA, or selected IIIB (T3N2 only) NSCLC of squamous or non-squamous histology. Staging should be based on the 8th edition of the American Joint Committee on Cancer (AJCC)/Union Internationale Contre le Cancer (UICC) NSCLC staging system - T4 primary NSCLC will be allowed only on the basis of size. Invasion of the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina, and separate tumor nodules in a different ipsilateral lobe is not permitted - All participants will undergo clinical staging using computed tomography (CT) and positron emission tomography (PET) scanning, as well as brain imaging using magnetic resonance imaging (MRI). Invasive mediastinal staging by either mediastinoscopyor endo- bronchial ultrasonography is highly encouraged for participants with radiographically suspected mediastinal nodal disease (ie, N2) but not mandated if the CT or PET scans showed no evidence of N2 disease - Molecular testing results from clinical laboratory improvement amendments (CLIA)-certified laboratories and showing at least one of the following abnormalities: ALK fusion, ROS1 fusion, NTRK1/2/3 fusion; BRAF V600 mutation, RET fusion, PD-L1 expression in ≥ 1% tumor cells as determined by FDA-approved test, KRAS G12C mutation - Measurable disease, as defined by RECIST v1.1 - NSCLC must have a solid or subsolid appearance on CT scan and cannot have a purely ground glass opacity appearance. For subsolid lesions, the tumor size (i.e., clinical T stage) should be measured based on the solid component only, exclusive of the ground glass opacity component - Evaluated by the attending surgeon prior to study enrollment to verify that the primary tumor and any involved lymph nodes are technically completely resectable and verify that the participant is medically operable - Adequate pulmonary function to be eligible for surgical resection with curative intent - Adequate cardiac function to be eligible for surgical resection with curative intent - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 - Adequate hematologic and end-organ function - Negative hepatitis B surface antigen (HBsAg) test at screening for cohort - Negative total hepatitits B core antibody (HBcAb) test at screening for cohort, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) deoxyribonucleic acid (DNA) test at screening - Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV ribonucleic acid (RNA) test at screening - Male participants must be willing to use acceptable methods of contraception - Female participants of childbearing potential must agree to use acceptable methods of contraception Inclusion Criteria for Adjuvant Therapy (TKI Cohorts and KRAS G12C cohort [if continuing on Divarasib]): - Participants whose tumors lack radiographic progression - ECOG Performance Status of 0 or 1 - Adequate hematologic and end-organ function

Exclusion Criteria

  • NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease - Any prior therapy for lung cancer, including chemotherapy, targeted therapy, immunotherapy, or radiotherapy, within 2 years - Participants with prior lung cancer - Major surgical procedure within 28 days prior to Cycle 1, Day 1 - Malignancies other than the disease under study within 3 years prior to Cycle 1, Day 1, with the exception of participants with a negligible risk of metastasis or death and with expected curative outcome - Treatment with an investigational agent for any condition within 4 weeks prior to Cycle 1, Day 1 - Participants known to be positive for human immunodeficiency virus (HIV) are excluded if they meet any of the following criteria: cluster of differentiation 4 (CD4)+ T-cell count of <350 cells/microliters (cells/µL); detectable HIV viral load; history of an opportunistic infection within the past 12 months; on stable antiretroviral therapy for <4 weeks - Severe infection within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infections, or any active infection that, in the opinion of the investigator, could impact participant safety - Pregnant or lactating, or intending to become pregnant during the study

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
ALK Cohort (Enrolment Closed) 		Participants will receive up to 8 weeks of alectinib neoadjuvant treatment before undergoing surgical resection per standard of care (SOC). All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with alectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of alectinib. Enrolment Closed.
  • Drug: Alectinib
    Participants will receive oral alectinib twice per day (BID).
  • Procedure: Resection
    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
  • Drug: Chemotherapy
    Participants will receive SOC chemotherapy as determined by the treating physician.
Experimental
ROS 1 Cohort (Enrolment Closed) 		Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib. Enrolment Closed.
  • Drug: Entrectinib
    Participants will receive oral entrectinib daily.
  • Procedure: Resection
    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
  • Drug: Chemotherapy
    Participants will receive SOC chemotherapy as determined by the treating physician.
Experimental
NTRK Cohort (Enrolment Closed) 		Participants will receive up to 8 weeks of entrectinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with entrectinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of entrectinib. Enrolment Closed.
  • Drug: Entrectinib
    Participants will receive oral entrectinib daily.
  • Procedure: Resection
    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
  • Drug: Chemotherapy
    Participants will receive SOC chemotherapy as determined by the treating physician.
Experimental
BRAF Cohort (No Participants Enrolled, Cohort Closed) 		Participants will receive up to 8 weeks of vemurafenib plus cobimetinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with vemurafenib plus cobimetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of of vemurafenib plus cobimetinib. Cohort closed.
  • Drug: Vemurafenib
    Participants will receive oral vemurafenib BID.
  • Drug: Cobimetinib
    Participants will receive oral cobimetinib daily.
  • Procedure: Resection
    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
  • Drug: Chemotherapy
    Participants will receive SOC chemotherapy as determined by the treating physician.
Experimental
RET Cohort (Cohort closed) 		Participants will receive up to 8 weeks of pralsetinib neoadjuvant treatment before undergoing surgical resection per SOC. All participants that undergo surgical resection and whose tumors have pathological response or lack radiographic progression will be eligible for the adjuvant treatment phase with pralsetinib. Adjuvant therapy will consist of 4 cycles of chemotherapy followed by up to 2 years of pralsetinib. Cohort closed.
  • Drug: Pralsetinib
    Participants will receive oral pralsetinib daily.
  • Procedure: Resection
    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
  • Drug: Chemotherapy
    Participants will receive SOC chemotherapy as determined by the treating physician.
Experimental
PD-L1 Cohort (Enrolment Closed) 		Participants with positive programmed death-ligand 1 (PD-L1) in ≥1% tumor cells will receive 4 cycles of atezolizumab neoadjuvant treatment. During neoadjuvant Cycle 1 of atezolizumab, participants will also receive low-dose stereotactic body radiation therapy (SBRT) (8 gray [Gy] X 3). Adjuvant treatment consists of SOC treatment as determined by the investigator, per National Comprehensive Cancer Network (NCCN) guidelines. Enrolment Closed.
  • Drug: Atezolizumab
    Atezolizumab will be administered by intravenous (IV) infusion.
  • Drug: SBRT
    Participants will receive SBRT given concurrently, starting with the first dose of atezolizumab.
  • Procedure: Resection
    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
Experimental
KRAS G12C Cohort 		Participants will receive up to 8 weeks of divarasib as neoadjuvant treatment before undergoing surgical resection per SOC. PD-L1 negative participants whose tumors have pathological response or lack radiographic progression will be have the option of continuing divarasib alone for up to 3 years or 1-4 cycles of SOC chemotherapy followed by divarasib for 3 years as adjuvant therapy. For participants who test positive PD-L1, they will have the option to receive 1-4 cycles of SOC chemotherapy followed by atezolizumab for up to 16 cycles or SOC alone.
  • Procedure: Resection
    Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
  • Drug: Chemotherapy
    Participants will receive SOC chemotherapy as determined by the treating physician.
  • Drug: Divarasib
    Participants in the KRAS G12C cohort will receive oral divarasib for approximately 8 weeks until the day before surgery as neoadjuvant therapy up to 3 years as adjuvant therapy.

Recruiting Locations

MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
Washington D.C. 4140963, District of Columbia 4138106 20007

More Details

Status
Recruiting
Sponsor
Genentech, Inc.

Study Contact

Reference Study ID Number: ML41591 https://forpatients.roche.com/
888-662-6728
global-roche-genentech-trials@gene.com